Is Straterra (atomoxetine) effective for treating high anxiety and Attention Deficit Hyperactivity Disorder (ADHD)?

Strattera (Atomoxetine) for High Anxiety and ADHD

Strattera is a reasonable option for treating ADHD with comorbid high anxiety, but stimulants remain first-line and often improve both conditions simultaneously—atomoxetine should be considered when stimulants are contraindicated, not tolerated, or when substance abuse risk is a concern. 1, 2

Treatment Algorithm Based on Anxiety Severity

When Stimulants Should Be First-Line (Most Cases)

• The American Academy of Child and Adolescent Psychiatry recommends initiating stimulant therapy as first-line treatment even when high anxiety is present, as stimulants achieve 70-80% response rates for ADHD and frequently reduce anxiety symptoms simultaneously without requiring additional medication. 1, 2

• Early concerns that stimulants worsen anxiety have been disproven—the MTA study demonstrated that ADHD patients with comorbid anxiety actually have better treatment responses to stimulants than those without anxiety. 1

• Stimulants work within days, allowing rapid assessment of whether both ADHD and anxiety symptoms improve, whereas atomoxetine requires 6-12 weeks to achieve full therapeutic effect. 1, 3

• If ADHD symptoms improve with stimulants but anxiety persists despite adequate trial, add an SSRI (fluoxetine or sertraline) to the stimulant regimen rather than switching to atomoxetine. 1, 2

When Atomoxetine Should Be First-Line

Consider atomoxetine as initial treatment in these specific contexts: 1, 2, 4

• Active substance use disorder or high risk for stimulant abuse/diversion (atomoxetine is not a controlled substance with negligible abuse potential) 3, 5
• Severe, treatment-resistant anxiety where stimulant activation is genuinely contraindicated 2
• Pre-existing severe sleep disorders (atomoxetine causes somnolence rather than insomnia) 3
• Patient/family refusal of controlled substances 5
• Comorbid tic disorders where stimulants may exacerbate symptoms 3

Atomoxetine Efficacy for Anxiety and ADHD

• Atomoxetine demonstrates efficacy for both ADHD and anxiety symptoms in children and adolescents with comorbid conditions, with marked reductions in both symptom clusters (p < 0.001). 6

• A systematic review confirmed that atomoxetine does not exacerbate and in fact reduces anxiety symptoms in young patients with comorbid ADHD and anxiety disorders. 7

• However, atomoxetine is significantly less effective than extended-release stimulants (OROS methylphenidate and mixed amphetamine salts) for core ADHD symptoms, though it is noninferior to immediate-release methylphenidate. 3

• The impressive efficacy of atomoxetine for both ADHD and anxiety symptoms challenges the traditional recommendation to start with stimulants, particularly in patients with prominent anxiety. 4

Dosing and Administration

• Starting dose: 40 mg orally daily 8
• Titration: Adjust every 7-14 days to 60 mg, then 80 mg daily 8
• Target dose for adults: 60-100 mg daily 1
• Maximum dose: The lesser of 1.4 mg/kg/day or 100 mg/day 8, 9
• Can be administered as single morning dose or split into two divided doses to reduce adverse effects. 3

Critical Safety Considerations

Black Box Warning: Suicidality

• The FDA requires a black box warning for atomoxetine due to increased risk of suicidal ideation in children and adolescents. 9

• Pooled analyses showed 0.4% (5/1,357) of atomoxetine-treated patients developed suicidal ideation versus 0% in placebo (0/851 patients), though no completed suicides occurred. 9

• Monitor closely for suicidality, clinical worsening, and unusual behavioral changes, especially during the first few months or at dose changes. 9

Cardiovascular Effects

• Atomoxetine causes statistically (but not clinically) significant increases in heart rate and blood pressure, though these effects are less pronounced than with stimulants. 1, 3

• Monitor blood pressure and pulse at baseline and regularly during treatment. 1

Hepatotoxicity

• Atomoxetine can cause severe liver injury in rare cases—three patients have had liver-related adverse events deemed probably related to atomoxetine. 3

• Discontinue immediately if jaundice, dark urine, right upper quadrant pain, or unexplained flu-like symptoms develop. 9

Common Adverse Effects

• Most common: Somnolence/fatigue, decreased appetite, nausea, vomiting, abdominal pain, headache 3, 5

• Somnolence is particularly problematic—do not prescribe atomoxetine first-line when fatigue is a chief complaint, as this directly contradicts the medication's adverse effect profile. 1

• Atomoxetine appears better tolerated among extensive CYP2D6 metabolizers than poor metabolizers (who have 10-fold higher plasma concentrations). 3

Drug Interactions

• SSRIs that inhibit CYP2D6 (fluoxetine, paroxetine) elevate atomoxetine levels, requiring dose adjustment when combining atomoxetine with these agents. 1, 6

• The combination of atomoxetine plus fluoxetine is well-tolerated and effective for ADHD with comorbid depression/anxiety, though blood pressure and pulse increases are greater with combination therapy. 6

• Never use atomoxetine with MAO inhibitors—at least 14 days must elapse between MAOI discontinuation and atomoxetine initiation. 9

Common Pitfalls to Avoid

• Do not assume atomoxetine will treat both ADHD and depression—despite initial development as an antidepressant, evidence does not support efficacy for comorbid depression. 1

• Do not underdose or give up too early—atomoxetine requires 6-12 weeks for full therapeutic effect, unlike stimulants that work within days. 1, 3

• Do not use atomoxetine as first-line when stimulants are appropriate—this chooses a less effective option with slower onset and deprives patients of the most effective treatment. 1

• Do not prescribe atomoxetine in patients with narrow-angle glaucoma or pheochromocytoma (absolute contraindications). 9

Multimodal Treatment Approach

• Pharmacological treatment must be part of a comprehensive approach including psychoeducation, behavioral therapy, and psychosocial interventions. 1

• Adjunctive cognitive-behavioral therapy (CBT) for anxiety is strongly recommended and considered superior to medication alone when anxiety persists despite adequate pharmacotherapy. 2, 4

• Combined treatment (medication plus CBT) shows superior outcomes for anxiety disorders, including improved global function, response rates, and remission rates compared to either alone. 1, 2